Balanced news tone
News Sentiment
ISOFOL sentiment intelligence
Isofol Medical AB (publ) news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
10 relevant articles
News tone and price action are not far from neutral.
88/100 classification confidence.
directly relevant articles
high-authority source matches
+2.5% over one week, +20.1% over four weeks, trend active, and below fair value.
Isofol begins final dose cohort on the way to Phase II
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
88/100 classification
One-week reaction
2.5%
Price confirming higher
Trend fit
Trend active
20.1% over four weeks
Fair value
-32.0%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
8
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Biostock
Direct company coverage
Isofol begins final dose cohort on the way to Phase II
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 15:21
- Source
- Biostock
TipRanks
Direct company coverage
Isofol advances arfolitixorin trial with final dose cohort in colorectal cancer study
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 10:07
- Source
- TipRanks
simplywall.st
Direct company coverage
We're Hopeful That Isofol Medical (STO:ISOFOL) Will Use Its Cash Wisely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 May 2026 07:00
- Source
- simplywall.st
TradingView
Direct company coverage
Isofol Medical AB (publ) publishes interim report, January – March 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 May 2026 07:00
- Source
- TradingView
Biostock
Direct company coverage
Isofol secures license for arfolitixorin in autism
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Mar 2026 07:00
- Source
- Biostock
Biostock
Direct company coverage
Strong preliminary phase Ib/II data from Isofol enables tumour surgery
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 25 Feb 2026 08:00
- Source
- Biostock
Biostock
Direct company coverage
Dose increase and strengthened cash flow in focus for Isofol Medical
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 19 Feb 2026 08:00
- Source
- Biostock
Biostock
Direct company coverage
European Patent Office gives green light for Isofol’s arfolitixorin
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Nov 2025 08:00
- Source
- Biostock
Biostock
Direct company coverage
Isofol reaches new phase Ib/II milestones in Europe – prepares Japanese study with Solasia
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Nov 2025 08:00
- Source
- Biostock
Biostock
Direct company coverage
Green Light for Higher Doses in Isofol’s Arfolitixorin Study
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 01 Oct 2025 07:00
- Source
- Biostock